Exelixis, Inc. (NASDAQ:EXEL) Given Average Rating of “Hold” by Brokerages

Exelixis, Inc. (NASDAQ:EXEL) has been given an average recommendation of “Hold” by the twenty-four brokerages that are presently covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, ten have given a hold recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $46.1579.

EXEL has been the subject of several research reports. TD Cowen reissued a “buy” rating on shares of Exelixis in a report on Wednesday, November 5th. HC Wainwright reaffirmed a “buy” rating and set a $52.00 price target on shares of Exelixis in a research report on Tuesday, February 3rd. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $45.00 price objective on shares of Exelixis in a research note on Tuesday, October 21st. Weiss Ratings restated a “buy (b)” rating on shares of Exelixis in a research report on Thursday, January 22nd. Finally, Wells Fargo & Company lowered their target price on shares of Exelixis from $36.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Tuesday, October 21st.

Exelixis News Roundup

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Zacks Research upgraded Exelixis from a “hold” to a “strong‑buy,” signaling increased analyst conviction that the company’s growth story is improving. Read More.
• Positive Sentiment: Zacks issued broad upward revisions to Exelixis’ earnings outlook — raising FY2026 to $2.76 from $2.34 and FY2027 to $3.65 (previously $3.30), and lifting several quarterly estimates (e.g., Q1‑Q4 2026 and Q1‑Q4 2027). These higher forward EPS forecasts support a re‑rating and provide a clearer path to earnings growth. Read More.
• Positive Sentiment: Zacks published a bullish write‑up, “3 Reasons Why Growth Investors Shouldn’t Overlook Exelixis,” highlighting growth attributes that could help EXEL outperform — a narrative that can attract growth‑oriented buyers. Read More.
• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating on EXEL, providing additional sell‑side support that may encourage institutional interest. Read More.
• Neutral Sentiment: Note that Zacks’ upgraded forecasts exceed the current broader consensus (the entries cite a consensus near $2.04 for the current year). The market may await confirmation from Exelixis’ upcoming results/sales trends before other analysts materially follow, which could create short‑term volatility. Read More.

Insider Buying and Selling at Exelixis

In other news, Director Mary C. Beckerle sold 24,622 shares of the stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $41.93, for a total transaction of $1,032,400.46. Following the completion of the sale, the director owned 21,380 shares in the company, valued at approximately $896,463.40. This represents a 53.52% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Dana Aftab sold 48,383 shares of the firm’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $42.50, for a total value of $2,056,277.50. Following the transaction, the executive vice president directly owned 664,778 shares in the company, valued at approximately $28,253,065. This represents a 6.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 245,235 shares of company stock valued at $10,490,600 over the last ninety days. 2.82% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Exelixis

Several large investors have recently modified their holdings of the stock. Farallon Capital Management LLC grew its position in Exelixis by 21.6% in the 3rd quarter. Farallon Capital Management LLC now owns 19,501,500 shares of the biotechnology company’s stock valued at $805,412,000 after buying an additional 3,466,000 shares during the last quarter. Assetmark Inc. boosted its holdings in shares of Exelixis by 1,230.8% in the third quarter. Assetmark Inc. now owns 3,195,971 shares of the biotechnology company’s stock valued at $131,994,000 after acquiring an additional 2,955,813 shares in the last quarter. Norges Bank purchased a new stake in shares of Exelixis in the second quarter valued at about $122,099,000. Qube Research & Technologies Ltd increased its stake in shares of Exelixis by 120.5% during the second quarter. Qube Research & Technologies Ltd now owns 3,047,222 shares of the biotechnology company’s stock worth $134,306,000 after acquiring an additional 1,665,110 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its holdings in Exelixis by 42.9% during the second quarter. Arrowstreet Capital Limited Partnership now owns 5,262,643 shares of the biotechnology company’s stock worth $231,951,000 after purchasing an additional 1,580,567 shares in the last quarter. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Exelixis Price Performance

Shares of NASDAQ:EXEL opened at $43.90 on Monday. Exelixis has a 12 month low of $32.38 and a 12 month high of $49.62. The firm has a market capitalization of $11.77 billion, a P/E ratio of 18.52, a P/E/G ratio of 0.74 and a beta of 0.42. The company’s fifty day moving average price is $43.69 and its 200 day moving average price is $40.95.

About Exelixis

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.